Lenvatinib, MK-1308A, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma

This study is looking at new treatments for advanced liver cancer in people who haven't had treatment before. Researchers want to see how safe the new treatment is and if it can help slow down or shrink the cancer. It combines a new medicine called MK-1308A with an existing drug, Lenvatinib.